AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06413173 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS and Cognitive Training Intervention
Description: Cognitive training will occur concurrently with sham tDCS session. The cognitive training occurs on a computer and consists of 5 exercises specifically selected and scientifically supported to (i) place demands on the executive function system (e.g. working memory, behavioral inhibition, decision making, and set- shifting), (ii) adapt to challenge the participant's current ability level, (iii) provide ongoing feedback, and (iv) present novel stimuli across visual and auditory modalities During each 45-minute training period, participants will complete the daily assigned adaptive training module. Following the completion of training sessions 1, 5, and 10, participants will be asked to supply a subjective workload assessment.
Study NCT06346262 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMART RM
Description: The SMART-RM will consist of 8 group-format, 45-60 minute sessions (up to 11 participants per group), which will be collaboratively delivered by a Nurse Educator (NE) and a Peer Educator (PE).
Study NCT06346262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valtoco Nasal Product
Description: Medication dosing will follow recommendations in the Valtoco package insert and managed by the epilepsy clinician.
Study NCT04886804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zongertinib
Description: zongertinib
Study NCT06248710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin nasal spray
Description: Syntocinon nose spray is usually applied in the context of labour and breast feeding. In this study, however, it will be used to induce an oxytocin (OT) release. Participants will apply three sprays in each nostril which will result in a dose of 24 I.U of oxytocin per participant
Study NCT06248710 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Animal-Assisted Intervention
Description: The dogs involved in the study are trained and used to work with different people in animal-assisted interventions. The dog will be familiarized with the room and the material as well as the staff of the study. The dog will be specifically trained for this study. The dog will be involved for a maximum of 3 sessions per day (approx. 20 minutes in total) and 2 days per week.
Study NCT06248710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The placebo nose spray contains a saltwater solution and will be applied like the Syntocinon nose spray containing oxytocin.
Study NCT06248710 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo nose spray contains a saltwater solution and will be applied like the Syntocinon nose spray containing oxytocin.
Study NCT06611306 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: DE-iPTV
Description: Dose-escalated VMAT-based radiotherapy, as previously described in our planning study
Study NCT05692011 — intervention group
Intervention type: DEVICE
Intervention: blood purification(PS)
Description: After the sepsis patients were enrolled, they were treated with blood purification in CVVH mode with PS membrane, 24 hours per day, for 3 consecutive days
Study NCT05692011 — intervention group
Intervention type: DEVICE
Intervention: blood purification(AN69ST)
Description: After the sepsis patients were enrolled, they were treated with blood purification in CVVH mode with AN69ST membrane, 24 hours per day, for 3 consecutive days
Study NCT06671119 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gastric Mucosal Ablation (GMA)
Description: Endoscopic Gastric Mucosal Ablation (GMA) after sleeve gastrectomy
Study NCT06675916 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PENG Block with lidocaine hydrochloride
Description: Intervention is ultrasound-guided PENG block analgesia with lidocaine hydrochloride
Study NCT06675916 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intra-articular infiltration with lidocaine hydrochloride
Description: Intervention is intra-articular analgesia with lidocaine hydrochloride
Study NCT06673888 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resin modified glass ionomer
Description: Resin modified glass ionomer (RMGI) is utilized for a variety of purposes, as luting agents, liners/bases, and restorative materials. The RMGI is more aesthetically pleasing than the conventional glass ionomer while maintaining the clinical benefits of the former, such as the release of fluoride, recharging capabilities, prevention of decalcification of hard tooth tissue, inhibition of bacterial acid metabolism, and ease of clinical operation.
Study NCT06673888 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: alkasite based restorative material
Description: Cention forte is bioactive restorative material which has the ability to remineralize hard dental tissues through calcium and fluoride release and can also neutralize bacterial acids through hydroxide ions release.
Study NCT06598761 — intervention group
Intervention type: COMBINATION_PRODUCT
Intervention: Immunotherapy+radiotherapy
Description: Adjuvant Immunotherapy: Immunotherapy drug of choice is tirilizumab, which has received national recommendations in metastatic uroepithelial cancer. Tirelizumab 200mg Q3w; the duration of immunotherapy is recommended for at least 1 year.~Adjuvant radiotherapy can be given concurrently or sequentially with adjuvant immunotherapy; it is recommended that radiotherapy can be started within 4-6 weeks after surgery. Rotational intensity-modulated radiotherapy (VMAT), daily image-guided radiotherapy (Daily IGRT) techniques are used.
Study NCT06598761 — intervention group
Intervention type: OTHER
Intervention: surveillance alone
Description: Patients recieve surveillance alone without any adjuvant interventions until any disease progression endpoints occur.
Study NCT05373901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dinutuximab Beta
Description: Dinutuximab beta was administered intravenously at a dosage of 10 milligrams/ meters squared (mg/m2) per day for 10 consecutive days
Study NCT05373901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 13-cis-Retinoic Acid
Description: 13-cis-Retinoic Acid was administered orally at a daily total dose of 160 mg/m2, divided into approximately two equal doses given twice daily for 14 days following the conclusion of dinutuximab beta infusion.
Study NCT05566678 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cigarette
Description: Subjects who self-selected to continue smoking their own preferred brand of commercially available cigarettes.
Study NCT05566678 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: THS
Description: Subjects who self-selected to quit smoking during the study duration will switch from cigarettes to using THS.
Study NCT05566678 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Smoking Abstinence
Description: Subjects who self-selected to quit smoking may be prescribed Nicotine Replacement Therapy (NRT) to support them in remaining abstinent from use of any tobacco and nicotine containing products during the study. (Behavioral support will be provided to subjects to aid with abstinence.)
Study NCT06334016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis sativa Extract
Description: Vape THC
Study NCT04963712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zadaxin
Description: 1.6 mg subcutaneous injection, once a day in the first 2 weeks, and 1.6 mg subcutaneous injection, twice a week in the successive 22 weeks.
Study NCT04513132 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: active-dTMS
Description: The dTMS using H-coil with 5Hz stimulate ACC. The sessions of dTMS will be conducted twice daily for 5 consecutive days, and twice sessions of a day will be separated by 3 hours at least.
Study NCT06334016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine
Description: Vape active nicotine
Study NCT05933824 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LP-98 injection
Description: Part A is administration is by subcutaneous LP98/placebo,Part B is administration is by intravenous drip LP98/placebo
Study NCT05150145 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherpy will be performed to thoracic and liver metastasis after chemotherapy.
Description: Intensity modulated radiotherapy will be performed to liver metastasis and thoracic SCLC patients who achieved CR or PR after chemotherapy .
Study NCT06334016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Administration
Description: Vape placebo nicotine
Study NCT05597098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cantharidin
Description: 0.1% cantharidin solution in acetone from 0.7% stock solution of cantharone is prepared and applied immediately. 10 μl of cantharidin per disc.
Study NCT05263141 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: retro-auricular single-site endoscopic thyroidectomy
Description: The strap muscles and the sternocleidomastoid muscle were separated. Upper parathyroid and lower parathyroid glands were identified and preserved. The recurrent laryngeal nerve (RLN) was identified，A lobe of thyroid specimen and central lymph nodes were dissected.
Study NCT05263141 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: traditional open surgery thyroidectomy
Description: The strap muscles were separated in the midline to expose the thyroid gland. Upper parathyroid and lower parathyroid glands were identified and preserved. The recurrent laryngeal nerve (RLN) was identified， a lobe of thyroid specimen and central lymph nodes were dissected.
Study NCT06129903 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: referral to the Memorial Sloan-Kettering Cancer Center (MSK) Department of Psychiatry and Behavioral Sciences.
Description: The primary intervention in this study is referral to the Memorial Sloan-Kettering Cancer Center (MSK) Department of Psychiatry and Behavioral Sciences. This study will not dictate specific psychiatry interventions beyond providing the referral.
Study NCT06673576 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Complete crown technique for superimposition
Description: the complete crown technique, the crown of the tooth corresponding to the gingival margin under evaluation will be selected using the paint method and circular selection tool. The same selection process will be applied to the moving model.
Study NCT06673576 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Gold standard technique for superimposition
Description: the gold standard technique, adjacent intact teeth and a portion of the palatal gingiva will be selected. Superimpositions will be executed utilizing the software's iterative closest point algorithm (ICP).
Study NCT06334016 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT05599360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vyxeos
Description: Vyxeos (daunorubicin and cytarabine) liposome for injection
Study NCT05599360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mylotarg
Description: Gemtuzumab ozogamicin is an antibody-drug conjugate (ADC) composed of the CD33-directed monoclonal antibody (hP67.6; recombinant humanized immunoglobulin \[Ig\] G4, kappa antibody produced by mammalian cell culture in non-secreting 0 (NS0) cells) that is covalently linked to the cytotoxic agent N-acetyl gamma calicheamicin. Gemtuzumab ozogamicin consists of conjugated and unconjugated gemtuzumab. The conjugated molecules differ in the number of activated calicheamicin derivative moieties attached to gemtuzumab. The number of conjugated calicheamicin derivatives per gemtuzumab molecule ranges from predominantly zero to 6, with an average of 2 to 3 moles of calicheamicin derivative per mole of gemtuzumab.
Study NCT06448572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EXL01
Description: 1 capsule / day
Study NCT04965883 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Excision and Grafting
Description: reconstruction of deep burn by grafting
Study NCT04965883 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dressing then delayed grafting
Description: multiple dressing and delayed grafting
Study NCT04740255 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Straberi Epistamp
Description: The patient's entire face will be treated. The following settings will be used as a treatment protocol. Needle length between .02- 1.55 mm
Study NCT05153174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulforaphane
Description: This is an over-the counter nutritional supplement. Participants will be given the extra strength tablets.
Study NCT05665855 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketone monoester
Description: A commercial liquid ketone monoester supplement.
Study NCT05665855 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A liquid placebo that is taste-matched to the ketone monoester supplement.
Study NCT05933655 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Coach
Description: Peer coaching session to support shared decision making among patient with limited health literacy.
Study NCT04513132 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham-dTMS
Description: The sham-dTMS has the same appearance with the real stimulation coil, which can not generate magnetic field. A sound generator is built in the coil beat to simulate the sound of the real stimulation.
Study NCT05164835 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmaceutical follow-up
Description: Pharmaceutical follow-up over 1 year and pharmaceutical interviews during the various medical consultation appointments.~In addition to the usual care:~* Delivery of questionnaire at the time defined in the protocol. The questionnaires will be given during the waiting time of the patients at the University Hospital of Limoges.~* Extension of the duration of the usual interview by 10 minutes in order to collect the desired information.
Study NCT05771935 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ultrasound guided radial versus ulnar artery cannulation
Description: Ultrasound examination will be performed using a hockey stick, high frequency (5-10 MHz) ultrasound probe (S-NerveTM; SonoSite Inc., Bothell, WA, USA).~. Arterial cannulation will be performed using the long axis view (in-plane) technique with a 24 or 22-gauge canulae according to the operator preference. Cannulation will be considered complete when the arterial waveform is confirmed on the monitor. If cannulation is unsuccessful within the third attempt or within 10 min, the case will be considered a failure at the chosen artery. After the failure, an alternative site will be used for cannulation and the case will be excluded from the study.
Study NCT05771935 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound guided radial versus ulnar artery cannulation
Description: Ultrasound examination will be performed using a hockey stick, high frequency (5-10 MHz) ultrasound probe (S-NerveTM; SonoSite Inc., Bothell, WA, USA).~. Arterial cannulation will be performed using the long axis view (in-plane) technique with a 24 or 22-gauge canulae according to the operator preference. Cannulation will be considered complete when the arterial waveform is confirmed on the monitor. If cannulation is unsuccessful within the third attempt or within 10 min, the case will be considered a failure at the chosen artery. After the failure, an alternative site will be used for cannulation and the case will be excluded from the study.
Study NCT05491538 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Cognition and Interaction Training-Work Edition (SCIT-WE)
Description: Participants will attend 1 2-hour skills training group weekly for 13 weeks after enrolling in supported employment. In addition to the group session, participants have a 15-30 minute individual session with the group facilitator weekly to review homework and complete a 10-15 minute exercise with their employment specialist each week to practice skills outside of group. The 13-week skills group is followed by 10 skills review/application sessions conducted during 10 supported employment sessions in the next 13 weeks.
Study NCT06666127 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LONG and SHORT Resistance Training
Description: One side of the body will be randomly assigned to perform exercises in position 3 (LONG) with the other randomly assigned to position 2 (SHORT) of Prime Fitness horizontal shoulder adduction, horizontal shoulder abduction, shoulder abduction and hip extension. Each exercise will include 1 warm up set at 50% 1RM followed by 4-5 sets of 8-12 repetitions per limb. 2 minutes of rest between sets on the same side of body will be administered as the participant will alternate between the right and left limb. The left and right side limbs will alternate each session in which one starts each exercise, resulting in 10 training sessions each where the left and right limbs starts first on each exercise. All sets will be performed to momentary failure. A Dynamic Double Progression will be employed to ensure intensity is maintained.
Study NCT06666127 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Maximal Isotonic Strength Testing (1RM)
Description: Each limb will perform a 1RM strength test with each Prime Fitness machine training horizontal shoulder adduction, horizontal shoulder abduction, shoulder abduction and hip extension respectively. Each machine will be set to position 1 (maximal load in mid-range). Testing will occur in weeks 1 and 12 of the study with the non-dominant arm and leg tested before the dominant arm and leg in each exercise. Participants self-selects first warm up set with a weight that is performed between 6-10 repetitions on both limbs. Rest for 1 minute between limbs and subsequent set. A weight is then selected by research staff to perform 3 repetitions with based on previous set. Load is now increased until 1RM is achieved. Rest periods should remain at least 1 minute alternating between limbs, with 1RM being complete within 3-5 attempts. Participant will rest 2-5 minutes before starting testing on the next exercise. Repeat for all exercises. Use pre testing data to inform 1RM attempts for post testing.
Study NCT06666127 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isokinetic Strength Testing
Description: Participants will engage in isokinetic strength testing on the isokinetic dynamometer (Biodex) in weeks 1 and 12 for each of the four movements: Horizontal shoulder adduction, horizontal shoulder abduction, shoulder abduction and hip extension. Participants will perform each movement unilaterally. Participants will start with the non-dominant arm and leg for each movement. Each movement will be tested through A maximal active range of motion. Participants will complete 10 sub-maximal repetitions to allow familiarization each movement. After a 2-minute rest, participants will complete 3 maximal concentric and eccentric repetitions with 30 seconds rest at 30 degrees per second before the Biodex is reset for the next movement.
Study NCT06666127 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Muscle Oxygenation
Description: During the first and last LONG and SHORT training session (visit 5 and visit 24), A near infrared spectroscopy sensor (NIRS device) (Trainred) will be affixed to the muscle belly of the deltoid during the lateral raise exercise to measure muscle oxygenation.
Study NCT05348473 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Alpha type
Description: Tips of the seton will be tied as alpha-shaped.
Study NCT05348473 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Beta type
Description: Tips of the seton in this group will be overlapped and tied
Study NCT05348473 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Comfort type
Description: Knotless seton will be applied
Study NCT06681584 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: CTCA
Description: CTCA is a non-invasive test for diagnosis of anatomic coronary stenosis. Additionally, the diagnostic performance of FFRB (derived from in house calculation) with CCTA data in patients with intermediate coronary artery disease (CAD), as compared to an invasive FFR reference standard (FFR\<=0.80)
Study NCT06681779 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical stimulation
Description: Transcutaneous electrical stimulation will be used to create noxious stimuli for the GCS exam
Study NCT03686657 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: 1000 mg metformin-HCL XR once-a-day or maintenance dose of metformin for 26 weeks
Study NCT03686657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Val, Cel and Met XR Low
Description: 500 mg metformin-HCL XR plus 100 mg celecoxib once-a-day in the morning and 160 mg valsartan 6 hours later once-a-day in the afternoon for 26 weeks.
Study NCT03686657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Val, Cel and Met XR High
Description: 1000 mg metformin-HCL XR plus 200 mg celecoxib once-a-day in the morning and 320 mg valsartan once-a-day 6 hours later in the afternoon for 26 weeks.
Study NCT06019780 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood flow restriction trainin
Description: Following exercise will be performed~1. Side lying external rotation~2. Prone horizontal abduction~3. Standing scaption İndividual in the group will be having two session per week, 16 session of exercise training for 8 weeks.50% of arterial occlusion pressure (60 to 80 mmHg) will be applied for total duration of 15mins. Occlusion pressure will be calculated according to formula for each patient \[Pressure=0.4x(systolic BP)+2.7x(shoulder circumference)+62\].4 sets with one set of 30 repetition and three sets of 15 repetition. After each set subject will have 30 seconds of rest with cuff inflated.